不同激素和注射方式对家猫超排效果的比较

比较了PMSG／hCG和FSH／hCG两种方案以及PMSG的不同剂量和注射方式对家猫的超排效果的影响。用100IU的PMSG超排家猫所得到的排卵点数及平均每只猫获得的卵数显著低于200IU处理组或300IU处理组（P＜0．05）,但200IU处理组与300IU处理组之间的超排效果也无显著差异（P＞0．05）;用皮下注射200IU的PMSG或用肌肉注射200IU的PMSG对超排效果无差异（P＞0．05）;用200IU PMSG／200IU hCG和1.5mg FSH/200IU hCG两种方案对家猫超排,发现不论是每只猫的排卵点数、卵子获得数,还是卵子的第一极体排放率都没有显著差异（P＞0．05）。实验说明,PMSG的注射方式不影响对家猫的超排效果,用200IU的PMSG超排家猫是较适合的剂量,FSH和PMSG都可用于家猫的超排,但PMSG使用更为方便。     

C57BL/6J小鼠超数排卵的研究

目的　确定C57BL 6J小鼠超排的最佳激素剂量和最合适的注射间隔时间 ,提高超排率。方法　 40只C57BL 6J雌鼠随机分为四组 ,分别用 5IU或 10IU的PMSG和HCG ,间隔 48h或 72h注射 ,比较排出卵母细胞的数量。结果　 5IU +5IU剂量的PMSG和HCG、间隔 48h注射组超排效果最好 ;8～ 10周龄雌鼠较 6～ 8周龄雌鼠超排效果好。结论　C57BL 6J小鼠超排的最佳激素剂量为 5IUPMSG +5IUHCG ,最合适的注射间隔时间为 48h ,处于繁殖期的雌鼠超排效果好。     

尿激酶及其抑制物对未成年小鼠排卵的影响

利用未成年小鼠超数排卵方法,研究了纤溶酶原激活因子——尿激酶和它的抑制物——6氨基己酸对排卵的作用。实验结果表明:18日龄小鼠在注射PMSG和hCG条件下,增注尿激酶800U,排卵动物数及平均排卵数与对照组比较有显著性差异。如果仅用PMSG和尿激酶,不能引起动物排卵。21日龄小鼠在注射PMSG后再注射不同剂量hCG情况下增注尿激酶,平均排卵数均比相应对照组有显著性差异,但hCG注射量为l.25IU组,增注尿激酶后,实验组与对照组平均排卵数无显著性差异。用尿激酶抑制剂6氨基己酸可以有效抑制超数排卵的效果。实验结果提示,尿激酶只有在hCG存在条件下对小鼠排卵有促进作用,而尿激酶本身不具有诱发排卵的作用。     

不同剂量孕马血清促性腺激素超排处理对家兔卵巢组织形态和胚胎发育的影响

为了研究不同剂量的孕马血清促性腺激素（PMSG）对家兔（Oryctolagus cuniculus f. domesticus）超排后,卵巢组织形态和PMSG对早期胚胎体外发育的影响。将24只家兔分为对照组、50 IU、70 IU和90 IU组,每组6只,对照组不做处理,后3组分别注射50 IU、70 IU和90 IU PMSG和定量100 IU人绒毛膜促性腺激素（HCG）对家兔进行超排处理。解剖后测定卵巢形态和组织参数。利用注射器抽取5ml冲卵液,分别从左右输卵管冲取胚胎至培养皿中,转至细胞培养室对胚胎进行体外培养观察。结果显示,PMSG处理组与对照组相比,随着PMSG注射剂量的增大,家兔卵巢重及宽度和厚度均极显著增大（P<0.01）,卵巢长度显著增长（P<0.05）,卵巢表面充血,卵泡数增多;另外,随PMSG注射剂量的增大,次级卵泡及其卵母细胞直径、三级卵泡直径均呈减小趋势（P <0.01）,三级卵泡中卵母细胞直径呈增大趋势,与对照组相比差异显著（P <0.05）;三级卵泡的直径和卵泡的优势化率,70 IU组显著高于对照组及50 IU和90 IU组（P &l...     

周龄和激素水平对长爪沙鼠超数排卵效果的影响

目的探讨不同周龄和激素水平对长爪沙鼠超数排卵效果的影响,以期确定长爪沙鼠最佳超排周龄和激素使用剂量。方法腹腔注射10 IU PMSG/HCG对4～18周龄8个年龄段的雌性长爪沙鼠进行超数排卵,末次注射16～17 h内对各组动物卵母细胞计数,确定最佳超排周龄后,对该年龄动物以5、10、15 IU3个剂量水平腹腔注射PMSG/HCG,观察各组动物的卵母细胞计数差异。结果与其它周龄组相比,6周龄组长爪沙鼠超数排卵后的卵母细胞数最多,各组间有统计学意义（P〈0.05）,而5、10、15IU等3个剂量组的超排效果也有一定的差异,10 IU组数量最高。结论对长爪沙鼠而言,采用10 IU激素注射和6周龄的动物进行超数排卵,获得的卵母细胞数量最多而且超排效果稳定性。     

LH与hCG对昆明小鼠卵母细胞体外成熟的影响

目的研究促黄体素（LH）、人绒毛膜促性腺激素（hCG）对昆明小鼠卵母细胞体外成熟的影响。方法小鼠经注射孕马血清促性腺激素（PMSG）48h后,摘取卵巢获得未成熟卵母细胞,分别在含不同浓度的LH和hCG的成熟液中,或将LH和hCG以不同的浓度组合加入到成熟液,进行体外成熟。结果经15.16h的成熟培养,5个浓度LH组中的极体率均高于对照组,其中200IU/mL组显著高于50IU/mL、400IU/mL、300IU/mL组和对照组（P〈0.05）;5个浓度hCG组的极体率与对照组极体率无显著差异（P〉0.05）;协同组中15IU/mL hCG＋200IU/mL LH组的极体率显著高于对照组和其它各处理组。结论LH对小鼠卵母细胞的体外成熟有一定的促进作用。     

山羊发情后期三种不同超排方法的比较

目的　研究在山羊发情后期三种不同超排方法的超排效果。方法　实验以 2 0只本地山羊为实验材料 ,以氯前列烯醇二次注射法进行同期发情 ,研究了于发情后期 (发情结束后第 2天 )进行 3种不同的超排方法 (对照组 :3 0 0IUFSH 6次减量法 ,F -pvp组 :3 0 0IUFSH溶于 3 0 %PVP一次注射 ,F -pmsg组 :先注射 2 0 0IUFSH ,2 4h后结合 3 3 0IUPMSG一次注射法 )的超排效果。结果　二次注射氯前列烯醇在 60h内同期率为 80 % (16 2 0 ) ,3种超排方法平均获黄体数分别为 9 75± 4 65,11 75± 8 3 4 ,11± 9 13 ;平均获可用胚数分别为 7± 2 94,8± 5 48,7 5± 5 80 ;胚胎回收率分别为 62 16% ,68 0 8% ,61 3 6%。t检验证明实验组 (F pvp组和F pmsg组 )平均获黄体和平均可用胚与对照组差异有显著性 (P <0 0 5) ,而胚胎回收率 (卡方检验 )差异无显著性 (P >0 0 5)。结论　山羊发情周期的发情后期进行超排能取得很好的卵巢反应 ,而且FSH一次注射法 (溶于 3 0 %PVP或 2 4h后结合少量PMSG)与多次减量法的超排效果一致 ,这表明 ,在山羊发情后期使用FSH一次注射的超排方法有可能作为一种简化的体内生产胚胎的方法加以进一步开发和应用     

幼年大鼠诱发排卵过程中卵巢PGS的变化及其生理作用

本实验用未年大白鼠经PMSG/hCG诱发排卵,观察了卵巢PGE_2,PGF_(2a),6-KetoPGF_(1a)和TXB_2在排卵过程中的变化,以及PGS合成抑制剂——消炎痛对大鼠排卵的抑制效应。实验结果表明:消炎痛在1mg/只的剂量下,对于大鼠体内排卵有显著的抑制作用。在hCG注射后19小时,正常组动物排卵数为14.4±4.3个/卵巢;消炎痛组排卵数为2.33±2.7个/卵巢。RIA结     

小鼠超数排卵优化试验方案研究

探讨建立一种适合贵州地区、高效、稳定的小鼠超数排卵优化方案。在饲养环境相同的基础上,对激素(PMSG, hCG)不同的剂量组合、注射间隔时间、小鼠周龄等影响因素进行了相关研究。试验结果表明:(1)平均采胚数量组间、平均异常胚组间与平均可用胚组间差异显著(p<0.05),注射10 IU的激素剂量组合获得受精卵最多,且异常胚最少,效果最佳。(2)第1、第2、第3组平均采胚数量组间差异显著(p<0.05),第1组与第2组平均可用胚组间差异不显著(p>0.05),但第1、2组与第3组差异显著(p<0.05),异常胚组间差异不显著(p>0.05),选择4周龄超排效果最佳。(3)第1、第2、第3组平均采胚数量、平均可用胚组间差异显著(p<0.05),平均异常胚组间差异不显著(p>0.05),PMSG,hCG间隔注射时间为48 h为最佳。     

体外重组的人促黄体素对小鼠早期胚胎发育的影响

为了研究人的重组促黄体素（r-hLH)对小鼠早期胚胎发育的作用,我们用一定剂量的r-hFSH(人促卵泡素,20IU）结合不同剂量的r-hLH（0－20IU）,或先与不同剂量r-hLH配比（5－20IU）,再与一定剂量,r-hLH（15IU）结合,对性成熟前的小鼠进行超数排卵;并对从其输卵管冲出的早期胚胎进行体外培养,通过观察这些早期胚胎体外发育情况,再与PMSG－hCG超排小鼠的早期胚胎体外培养结果进行比较。我们发现用重组激素处理的性成熟前小鼠,无论在平均冲胚数或桑囊率,囊胚率上,都以结合r-hLH或配比r-hLH的剂量为15IU时最好,但各重组激素处理组在桑囊率和囊胚率上都极显著低于PMSG－hCG对照组的相应指标。上述结果表明,r-hLH对小鼠早期胚胎的发育（尤其是囊胚的形成）有明显的抑制作用,且与r-hLH呈一定的剂量依赖性关系。     

Superovulation in immature and mature Chinese hamsters

Mature female Chinese hamsters ovulate an average of 8.8 ± 1.0 (mean ± SD) eggs per female in each estrous cycle. Superovulation can be induced in both immature and mature females by subcutaneous or intraperitoneal injections of pregnant mare serum gonadotropin (PMSG) and either human chorionic gonadotropin (hCG) or pituitary luteinizing hormone (PLH). The best superovulation in immature females was induced by the administration of 15 IU of PMSG followed 72 hr later by injection of 15 IU of hCG (about 25 eggs per female) or 0.2 mg (200 IU) PLH (about 46 eggs per female). Ovulation started about 13–15 hr after administration of hCG (or PLH) and was completed during the next 5–6 hr. Superovulation in mature females could be induced by injecting PMSG any day of the estrous cycle, but the best superovulation (about 39 eggs per female) was induced by injecting 15 IU of PMSG on day 1 (day of ovulation) followed by the injection of 0.4 mg of PLH 72 hr later. When immature females treated with the best superovulatory protocol were mated on the evening of PLH injection, only 5% of the eggs were found fertilized 50 hr after PLH administration. On the other hand, about 60% of the eggs were found fertilized in mature females mated following treatment with the best superovulatory protocol. The majority (83–85%) of superovulated eggs obtained from both immature and mature females were normally fertilized in vitro.     

Production of transgenic rats using young Sprague-Dawley females treated with PMSG and hCG.

The aim of this study was to examine the effects of gonadotrophin treatments on estrus synchronization and superovulation in young Sprague-Dawley (SD) rats that had not yet exhibited defined estrus cycles (5 to 7 weeks old), and to produce transgenic rats using these females as embryo donors and recipients. In Experiment 1, female rats were injected with PMSG and hCG (12.5, 25, 50 and 100 IU/kg each) and were mated with stud males. The reproductive performance of young rats were highest when PMSG and hCG at doses of 25 IU/kg each were injected (delivery rate 87.5%, nursing rate 92.9%). In Experiment 2, female rats were injected with PMSG and hCG (100, 150 and 300 IU/kg each) to induce superovulation. More eggs were recovered from the rats injected with PMSG and hCG at 150 and 300 IU/kg than from those treated with 100 IU/kg (33.4 and 41.3 vs. 13.3 eggs per female, respectively; p < 0.05). In Experiment 3, pronuclear-stage zygotes from 150 IU/kg PMSG/hCG-treated rats were used for microinjection of the fusion gene of bovine alpha S1-casein gene promoter and human growth hormone gene (2.8 kb), and the microinjected zygotes were transferred into the oviduct ampullae of the 25 IU/kg PMSG/hCG-treated rats. Seventeen transgenic rats were obtained from the 334 DNA-injected zygotes (5.1%). These results indicate that recipients and embryo donors for the production of transgenic rats can be prepared by the appropriate PMSG and hCG treatments of young SD rats, regardless of their estrus stages.     

Comparison between PMSG- and FSH-induced superovulation for the generation of transgenic rats

Superovulation protocols using single injections of pregnant mare's serum gonadotropin (PMSG) or minipumps with follicle-stimulating hormone (FSH) were compared in immature Sprague-Dawley (SD) rats. We used the following criteria: total number of ova, rate of fertilization, in vitro embryo development, sensitivity of zygotes to the microinjection of foreign DNA into the pronucleus, and their in-vivo development after transplantation into the oviduct of a recipient. Female SD rats were stimulated with 15 IU PMSG or 10 mg FSH followed by the injection of human chorionic gonadotropin (hCG) at doses of 20 and 30 IU per female. After hCG administration, they were mated with males of the same strain and sacrificed on day 1 of pregnancy. The percentage of mated animals and the fertilization rate was similar in all groups. In rats given PMSG, the number of ovulated zygotes was hCG dose-dependent. In contrast, the dose of hCG did not influence the efficiency of superovulation in rats given FSH, which was equal to PMSG-treated rats at the optimal dose of hCG. The rates of in vitro blastocyst development (31.4 and 23.3%) and the resistance to microinjection into the pronucleus did also not differ significantly between zygotes of both studied groups. The proportion of offspring developing from microinjected zygotes after oviduct transfer (26.2 and 26.8%, respectively) and the rate of transgene integration per newborns (7.3 and 4.9%, respectively) was similar in both experimental groups. The results of this study demonstrate that superovulation of immature SD rats by PMSG is equally effective as FSH treatment and, thus, preferable for transgenic rat technology due to the lower costs and easier handling.     

Induction of estrus in pubertal miniature gilts

Genetic engineering of miniature pigs has facilitated the development of numerous biomedical applications, such as xenotransplantation and animal models for human diseases. Manipulation of the estrus is one of the essential techniques for the generation of transgenic offspring. The purpose of the present study was to establish a useful method for induction of the estrus in miniature gilts. A total of 38 pubertal miniature gilts derived from 4 different strains were treated with exogenous gonadotropins. Estrus and ovulatory response were examined after treatment with pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) as 200 IU PMSG and 100 IU hCG, 300 IU PMSG and 150 IU hCG, or 1,500 IU PMSG only, followed by 100, 150 or 750 IU hCG 72 h later, respectively. The optimal protocol was determined to be the combination treatment of 200 IU PMSG and 100 IU hCG followed by 100 IU hCG. The administration of 200 IU PMSG and 100 IU hCG was effective in inducing estrus regardless of the strain, although there was a strain difference in the ovulatory response. These results indicate that treatment with a low-dose combination of PMSG and hCG provides one of the simplest methods for induction of estrus and ovulation in pubertal miniature pigs.     

Rat embryo quality and production efficiency are dependent on gonadotrophin dose in superovulatory treatments

The present study was performed to optimize a superovulation protocol in rats in order to produce a large number of good-quality embryos suitable to develop rat embryonic stem (rES) cells. We first evaluated the ovulation kinetics of three rat strains: Wistar, Fisher and ACI/N. Animals (n=30 per strain) were treated with 50 IU of pregnant mare serum gonadotrophin (PMSG), and ovulation was induced with 50 IU of human chorionic gonadotrophin (hCG) 50 h apart. Next, we evaluated the dose-response curves of PMSG and hCG in Wistar rats in order to obtain the highest number of embryos. The parameters evaluated for superovulation efficiency were: percentage of mated females, percentage of pregnant females and the average number of embryos collected per female. The results of these experiments suggested that the best dose combination was 50 IU for each hormone. Subsequent experiments, again with Wistar rats, were designed to test which of four hormonal combination treatments (30/30, 30/50, 50/30, and 50/50 IU of PMSG/hCG) will produce the largest numbers of good-quality embryos. Embryo quality was evaluated by embryo development uniformity, embryo morphology, embryo survival in an in vitro culture and embryo ability to generate rES-like cells. Results from these experiments showed that 30/50 IU of PMSG/hCG was the treatment that induced the best embryo quality. In conclusion, our results indicated that, in Wistar rats, the most appropriate hormonal combination dose for superovulation protocols with high number of good-quality embryos was 30 IU of PMSG and 50 IU of hCG given 50 h apart. We are performing further studies with rES-like cells produced with the present methodology to evaluate if they are able to participate in the production of germ-line chimeras.     

Evaluation of systems for collection of porcine zygotes for DNA microinjection and transfer

Crossbred gilts and sows (n=116) were used for the collection of 1-cell zygotes for DNA microinjection and transfer. Retrospectively, estrus synchronization and superovulation schemes were evaluated to assess practicality for zygote collection. Four synchronization and superovulation procedures were used: 1) sows were observed for natural estrous behavior; 1000 IU human chorionic gonadotrophin (hCG) was administered at the onset of estrus (NAT); 2) cyclic gilts were synchronized with 17.6 mg altrenogest (ALT)/day for 15 to 19 days followed by superovulation with 1500 IU pregnant mares serum gonadotropin (PMSG) and 500 IU hCG (LALT); 3) gilts between 11 and 16 days of the estrous cycle received 17.6 mg ALT for 5 to 9 days and PMSG and hCG were used to induce superovulation (SALT); and 4) precocious ovulation was induced in prepubertal gilts with PMSG and hCG (PRE). A total of 505 DNA microinjected embryos transferred into 17 recipients produced 7 litters and 50 piglets, of which 8 were transgenic. The NAT sows had less (P < 0.05) ovarian activity than gilts synchronized and superovulated by all the other procedures. Synchronization treatments with PMSG did not differ (P > 0.05) in the number of corpora hemorrhagica or unovulated follicles, but SALT and PRE treaments had higher ovulation rates than LALT (24.7 +/- 2.9, 24.3 +/- 1.8 vs 11.6 +/- 2.7 ovulations; X +/- SEM). The SALT and PRE treatments yielded 12.3 +/- 2.6 and 17.7 +/- 1.7 zygotes. Successful transgenesis was accomplished with SALT and PRE procedures for estrus synchronization and superovulation.     

Efficient collection and cryopreservation of embryos in F344 strain inbred rats

In rats, it is now possible to produce genetically engineered strains, not only as transgenic animals but also using gene knockout techniques. Reproductive technologies have been used as indispensable tools to produce and maintain these novel valuable strains. Although studies for collecting and cryopreserving embryos have been reported using outbred rats, efficient methods have not been established in inbred strains. The F344 inbred strain is important in rat breeding and has been used for the production of transgenic/knockout strains and for genome sequencing. Here we studied the optimal conditions for oocyte collection by induction of superovulation, and the development of embryos after cryopreservation in F344 rats. The response to pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) was examined by injection of 150 IU/kg PMSG + 75 IU/kg hCG or 300 IU/kg PMSG + 300 IU/kg hCG. Superovulation was achieved at high efficiency by an injection of 150 IU/kg PMSG + 75 IU/kg hCG. Furthermore, superovulation in this strain showed similar high response as Wistar rats. Of 2-cell embryos cryopreserved by vitrification in a solution containing 10% propylene glycol, 30% ethylene glycol, 20% Percoll and 0.3 M sucrose, more than 90% survived after warming and 32% developed to offspring. However, the freezability of pronuclear stage embryos was extremely low. This study demonstrated that sufficient unfertilized oocytes and embryos can be collected from F344 rats by the induction of superovulation with 150 IU/kg PMSG + 75 IU/kg hCG. Furthermore, cryopreservation of 2-cell embryos using this vitrification protocol can now be applied to maintaining valuable rat strains derived from the F344 inbred strain as genetic resources.     

Bimodal effects of luteinizing hormone and role of androgens in modifying superovulatory responses of rats to infusion with purified porcine follicle-stimulating hormone

Prepubertal (28-30 days old) female rats were infused s.c. over a 60-h period with a purified porcine pituitary follicle-stimulating hormone (FSH) preparation having FSH specific activity 8.4 times that of NIH-FSH-S1 and luteinizing hormone (LH) specific activity less than 0.005 times that of NIH-LH-S1, based on radioreceptor assays. When the FSH infusion rate of this preparation was increased over the range of 0.5-2 units/day (mg NIH-FSH-S1 equivalent), an all-or-none response was observed, with the threshold dose for superovulation being between 1 and 2 units/day. Eleven of twelve rats receiving the 2 units/day dose ovulated a mean +/- SEM of 67 +/- 8 oocytes on the morning of the third day after the beginning of FSH infusion. Addition of human chorionic gonadotrophin (hCG), as a source of LH activity, to a subthreshold (1 U/day) FSH infusion rate resulted in 20% of rats ovulating at an hCG dosage of 50 mIU/day; increasing the hCG infusion to 200 mIU/day concomitant with the subthreshold FSH infusion rate increased ovulation rate to a mean of 69 +/- 8/rat, with 100% of rats ovulating. To determine the effect of varying both FSH infusion rates and LH:FSH ratios, FSH was infused at several rates, with hCG added to give varying hCG:FSH ratios for each FSH infusion rate. Administration of hCG alone was ineffective in causing ovulation except at the highest infusion rates. Adding hCG to FSH to reach a ratio of 0.2 IU hCG/U FSH significantly increased the superovulatory response to an intermediate, 1 U/day FSH dose, but not to the low, 0.5 U/day dose.(ABSTRACT TRUNCATED AT 250 WORDS)